Rivulobirin E is primarily investigated for its potential antitumor and cytotoxic properties. It has shown activity in inhibiting the growth of certain cancer cell lines, making it a subject of interest in oncology research. Its mechanism appears to involve interference with cellular signaling pathways involved in proliferation and apoptosis. Due to its natural origin and unique structure, it serves as a lead compound in the development of novel chemotherapeutic agents. Studies are ongoing to evaluate its efficacy, stability, and delivery methods for possible use in targeted cancer therapies.